10-Q 1 NVE_Q1_FY2021_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 NVE CORPORATION (Exact name of regist ...

NVE Corporation (NASDAQ:NVEC) Q4 2020 Earnings Conference Call May 6, 2020 5:00 PM ET Company Participants Daniel Baker ??? President and Chief Executive Officer Curt Reynders ??? Chief Financial Officer Conference Call Participants Jeff Bernstein ??? Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the NVE Conference Call on Fourth Quarter and Fiscal Year Results. At this time, all participant lines are in a listen-only mode. After the speakers??? presentation, there will be q ...

10-K 1 NVE_2020_10K.htm ANNUAL REPORT FOR THE YEAR ENDED MARCH 31, 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-12196 NVE CORPORATION (Exact name of registrant as specified in its charter) St ...

NVE Corporation (NASDAQ:NVEC) Q3 2020 Results Conference Call January 22, 2020 5:00 PM ET Company Participants Daniel Baker - President and CEO Curt Reynders - CFO Conference Call Participants Jeff Bernstein - Cowen Operator Ladies and gentlemen, thank you for standing by and welcome to the NVE Third Quarter Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions] I would now like to turn the conference over to your speaker today, ...

10-Q 1 NVE_Q3_FY2020_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED DEC. 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 NVE CORPORATION (Exact name of re ...

NVE Corporation (NASDAQ:NVEC) Q2 2020 Earnings Conference Call October 23, 2019 5:00 PM ET Company Participants Daniel Baker - President and CEO Curt Reynders - CFO Conference Call Participants Thomas Cochran - Lake Road Partners Operator Good afternoon, ladies and gentlemen, and welcome to the NVE Conference Call on Second Quarter Results. [Operator Instructions] As a reminder, this conference call is being recorded. And now I would like to turn the conference over to your host, Mr. Dan Baker, President an ...

10-Q 1 NVE_Q2_FY2020_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED SEPT. 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 (Exact name of registrant as sp ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2020 decreased 11% year-over-year to $6.29 million from $7.11 million in the same quarter last year, attributed to an 11% decrease in product sales and a 12% decrease in contract R&D [6][8] - Gross margin increased to a record 83% from 80% in the first quarter last year due to a more profitable product mix [7] - Net income decreased 9% year-over-year to $3.61 million or $0.74 per diluted share compared to $3.95 million or $0.81 per share for the prior year quarter, but net income increased 26% sequentially [8][10] - Comprehensive income increased 9% to $4.18 million compared to $3.84 million for the prior year quarter, driven by a significant unrealized gain from marketable securities [9] Business Line Data and Key Metrics Changes - Anti-tamper product sales were strong, but the medical device market continued to be weak [6] - The company introduced a new smart TMR magnetometer called the SM225, which is designed for Internet of Things applications [11][12] - Revenues from new smart sensors are expected to grow as they are well received in the market, with a recent design win for a Bluetooth connected smart tape measure [13][14] Market Data and Key Metrics Changes - The medical device market remains challenging, but long-term demographics are positive, indicating a growing need for medical devices due to an aging population [29] - The company added a new representative in Europe to enhance sales efforts, indicating a strategic focus on expanding market presence [18] Company Strategy and Development Direction - The company is focusing on product development in smart sensors and power conversion ICs, aiming to improve efficiency in motor controls [33][34] - There is an ongoing interest in the biosensor technology for early-stage cancer detection, with plans to either market it independently or through licensing arrangements [41][42] - The company is committed to maintaining a strong balance sheet while continuing to pay dividends, with over $90 million paid in total dividends [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sequential sales growth in the upcoming quarter, with expectations of returning to year-over-year growth [26] - The company acknowledges challenges in the medical device market but sees long-term opportunities due to demographic trends [29] - Management is prepared to invest in long-term projects, particularly in the neurostimulator market, which is expected to grow despite current challenges [30][31] Other Important Information - The company is celebrating its 30th anniversary and will demonstrate new products at the upcoming annual shareholders meeting [20] - The company has engaged a new accounting firm, Boulay PLLP, for better governance and efficiency [23] Q&A Session Summary Question: Insights on Abbott's CRM business and visibility - Management noted Abbott's sequential sales growth and expressed confidence in achieving sequential sales growth in their own third quarter [26] Question: Competitors in the CRM market - Management refrained from discussing specific competitors but emphasized their strong position in the medical device market [27] Question: Focus areas in neurostimulators - Management indicated a focus on various applications, including pain management and neurological disorders, while acknowledging regulatory challenges [30][31] Question: Changes in product development focus - Management explained the addition of power conversion ICs for motor controls and clarified that medical diagnostics remains an area of interest [32][35] Question: Licensing technology for biosensors - Management confirmed the possibility of licensing technology or forming partnerships with larger companies for market entry [41][42] Question: Details on unclonable functions business - Management described the business as high value-added systems primarily used in military applications, with rigorous testing and variable margins [48][50] Question: Private label couplers - Management explained that private label couplers are sold under other companies' brand names, which helps reach different customer segments [52][54]

10-Q 1 NVE_Q1_FY2020_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) 11409 Valley View Road, Eden Prairie, Minnesota 55344 (Address of principal executive offices) (Zip Code) (952) 829-9217 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during th ...

NVE Corporation (NASDAQ:NVEC) Q4 2019 Earnings Conference Call May 1, 2019 5:00 PM ET Company Participants Dan Baker - President and Chief Executive Officer Curt Reynders - Chief Financial Officer Conference Call Participants Jeff Bernstein - Cowen Operator Good day, ladies and gentlemen, and welcome to the NVE Conference Call on Fourth Quarter and Fiscal Year Results Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Dan ...